U.S. Food and Drug Administration (FDA) and European Commission have granted Orphan Drug Designation to deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disease. Deupirfenidone...
MSD outside of the United States and Canada, announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in infants and...
completed treatment without interruption. At three months post-treatment, local control within the re-irradiated volume was 100%, with complete metabolic response, partial response, or stable disease observed in all evaluable patients. Acute...
Precision AQ, a global commercialisation partner built to guide life science innovators through commercial complexity, announced the appointment of two new leaders who will accelerate the company's international growth and enhance delivery of...
Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustained efficacy, safety, and persistence through to Week 102. The data will be presented as a poster presentation at the 21st Congress of the European Crohn’s and Colitis...
IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings, published in Nature...
levels (as low as 40 ppm) suppressed genes associated with proliferation and drug resistance (e.g., MYCN, ETS2, ABCB1), while high deuterium environments (300 ppm) upregulated multiple oncogenic and survival pathways (EGFR, CTNNB1, STAT3, CD44)....
affects communication between nerves and muscles.¹ RYSTIGGO® is administered as a weekly infusion of 3mL-6mL of drug over 15-30 minutes for 6 weeks, with subsequent treatment cycles based on clinical evaluation.¹ “With this new FDA clearance, we...
Corp. a fully integrated, commercial biotechnology company, presented data on TONMYA™, which was investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit, on January 29, 2026, in Boston, Massachusetts. A copy of the Company's...
virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry...
lenalidomide and dexamethasone (VRd) in NDMM patients who were ineligible for ASCT or deferred ASCT as initial therapy.1 Today's milestone follows approval for D-VRd for the treatment of patients who are newly diagnosed with multiple myeloma and...
Privo Technologies, Inc. announced the successful completion of its Phase 1/2 clinical evaluation of PRV211, a first-in-class intraoperative chemotherapy patch for head and neck cancer patients. The study demonstrated excellent safety outcomes...
modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models....
pharmacy specializing in personalized medication services, announced a strategic New Year's expansion of its compounded GLP-1 weight management program. The expansion provides increased access to compounded tirzepatide and semaglutide, perfectly...
OCuSOFT Inc. a privately-held eye care pharma company recognized as developing the first eyelid hygiene cleansing agent, proudly announces the launch of Retaine® Omega Forté™, a highly purified omega-3 nutritional supplement formulated to provide...
BIOCORNEUM®, the leading brand in professional scar and skin recovery, announced the immediate availability of its new Bruise Care System. The innovative dual-approach regimen is designed to help patients prepare for and recover more quickly from...
MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of orthobiologic solutions, announced the launch of...
For more than forty years, Trauma Intervention Programs (TIP) has stood beside individuals and families during their most devastating moments, providing immediate, on-scene emotional first aid in the aftermath of tragedy. TIP recently announced...
with user-centric design to maximize output and comfort: Hospital-Strength Power: Provides hospital-grade suction with 12 adjustable strength levels and 2-phase technology. Baby-Inspired Pumping Styles: Features three distinct pumping styles and a...
treatment for 30 eligible patients through CFAO’s Smiles4Canada program, a public health goodwill program founded in 2016 to put a smile, both figuratively and literally, on a young person with significant orthodontic needs, whose family does not...